159 related articles for article (PubMed ID: 30461630)
1. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.
Liu Y; Zhou C; Zhang K; Feng Y; Zhang R
Medicine (Baltimore); 2018 Nov; 97(47):e13259. PubMed ID: 30461630
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis.
Cheng H; Sun A; Guo Q; Zhang Y
Drug Des Devel Ther; 2018; 12():2173-2183. PubMed ID: 30034222
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Luo D; Wang L; Chen X; Xiong Y; Yi F; Ding J; Ding H; Wei Y; Zhang W
Chemotherapy; 2020; 65(1-2):11-20. PubMed ID: 32535588
[TBL] [Abstract][Full Text] [Related]
6. Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Ye Z; Zeng Y; Wei S; Wang Y; Lin Z; Chen S; Wang Z; Chen S; Chen L
BMC Cancer; 2021 Jun; 21(1):702. PubMed ID: 34126957
[TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis.
Qi J; Liu E; Yue H; Chen G; Liu Y; Chen J
Ann Palliat Med; 2021 Sep; 10(9):9902-9913. PubMed ID: 34551570
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
Ter Veer E; Mohammad NH; Lodder P; Ngai LL; Samaan M; van Oijen MG; van Laarhoven HW
Gastric Cancer; 2016 Jul; 19(3):696-712. PubMed ID: 26754295
[TBL] [Abstract][Full Text] [Related]
10. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian NN; Wang YH; Min GT
Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
[TBL] [Abstract][Full Text] [Related]
11. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis.
Wang L; Li J; Chen H
Chemotherapy; 2024; 69(1):11-22. PubMed ID: 37339610
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis.
Ma Y; Li J; Wen L; Zhang G; Yao X
World J Surg Oncol; 2023 Jun; 21(1):165. PubMed ID: 37264386
[TBL] [Abstract][Full Text] [Related]
15. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.
Huang J; Cao Y; Wu L; Liao C; He Y; Gao F
Med Oncol; 2011 Dec; 28(4):1004-11. PubMed ID: 20552300
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.
Wei Y; Liu J; Yan M; Zhao S; Long Y; Zhang W
Chemotherapy; 2019; 64(2):94-104. PubMed ID: 31569090
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
He AB; Peng XL; Song J; Zhang JX; Dong WG; Luo RF; Tang Y
World J Gastroenterol; 2015 Apr; 21(14):4358-64. PubMed ID: 25892887
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Liu H; Chen X; Sun J; Gao P; Song Y; Zhang N; Lu X; Xu H; Wang Z
Medicine (Baltimore); 2014 Nov; 93(25):e164. PubMed ID: 25437030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
